Quarterly ResultMay 15, 2026, 06:02 AM
ARS Pharmaceuticals Q1 2026 Revenue $22.7M; neffy Sales $17.5M
AI Summary
ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7 million, including $17.5 million in U.S. net product revenue from neffy sales. The company posted a net loss of $60.6 million, or ($0.61) per share, but maintains a cash position of $201.0 million, expected to fund operations through cash-flow break-even. Key commercial progress includes a CVS Caremark proposal in final stages, sales force expansion to 148 representatives, and FDA approval to remove age criteria for 1 mg neffy. Globally, neffy received Health Canada approval and EURneffy 1 mg received European Commission marketing authorization. The Phase 2b CSU study interim population is fully enrolled, with data anticipated in Q4 2026.
Key Highlights
- Q1 2026 total revenue was $22.7 million.
- Neffy U.S. net product revenue reached $17.5 million.
- Q1 2026 net loss was $60.6 million, or ($0.61) per share.
- Cash, cash equivalents, and short-term investments totaled $201.0 million as of March 31, 2026.
- Sales force expanded from 106 to 148 representatives.
- FDA approved removing age criteria for 1 mg neffy in late March 2026.
- Health Canada approved neffy on April 15, 2026.
- European Commission granted marketing authorization for EURneffy 1 mg on March 31, 2026.